Huang Shaohui, Gong Naying, Li Jiangbin, Hong Mingye, Li Li, Zhang Ling, Zhang Hua
Institute of Laboratory Medicine, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan, 523808, China.
Health Science Center, University of Texas, Houston, 77030, USA.
Biomark Res. 2022 Apr 7;10(1):18. doi: 10.1186/s40364-022-00368-2.
Neuroblastoma (NB) is a malignant tumor in young children that originates from the neural crest of the sympathetic nervous system. Generally, NB occurs in the adrenal glands, but it can also affect the nerve tissues of the neck, chest, abdomen, and pelvis. Understanding the pathophysiology of NB and developing novel therapeutic approaches are critical. Noncoding RNAs (ncRNAs) are associated with crucial aspects of pathology, metastasis and drug resistance in NB. Here, we summarized the pretranscriptional, transcriptional and posttranscriptional regulatory mechanisms of ncRNAs involved in NB, especially focusing on regulatory pathways. Furthermore, ncRNAs with the potential to serve as biomarkers for risk stratification, drug resistance and therapeutic targets are also discussed, highlighting the clinical application of ncRNAs in NB.
神经母细胞瘤（NB）是一种发生于幼儿的恶性肿瘤，起源于交感神经系统的神经嵴。一般来说，NB发生于肾上腺，但也可影响颈部、胸部、腹部和骨盆的神经组织。了解NB的病理生理学并开发新的治疗方法至关重要。非编码RNA（ncRNAs）与NB的病理学、转移和耐药性等关键方面相关。在此，我们总结了参与NB的ncRNAs的转录前、转录和转录后调控机制，尤其关注调控途径。此外，还讨论了有潜力作为风险分层、耐药性和治疗靶点生物标志物的ncRNAs，突出了ncRNAs在NB中的临床应用。
Zotero 插件
